Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis,[6] a type of myeloproliferative neoplasm that affects the bone marrow;[11][12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea;[6][13] and steroid-refractory acute graft-versus-host disease.[6] Ruxolitinib is a Janus kinase inhibitor.[6] It was developed and marketed by Incyte Corp in the US under the brand name Jakafi,[6] and by Novartis elsewhere in the world, under the brand name Jakavi.[14]
It was approved for medical use in the United States in 2011,[15] and in the European Union in 2012.[8] Ruxolitinib is the first FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients.[16]
^ ab"JAKAVI (Novartis Pharmaceuticals Australia Pty LTD) | Therapeutic Goods Administration (TGA)". Archived from the original on 8 March 2023. Retrieved 8 March 2023.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^https://www.tga.gov.au/resources/artg/198934 Archived 8 March 2023 at the Wayback Machine [bare URL]
^"Jakavi Product information". Health Canada. 22 October 2009. Archived from the original on 8 March 2023. Retrieved 7 March 2023.
^"Jakavi 10mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 5 April 2022. Archived from the original on 8 March 2023. Retrieved 7 March 2023.
^ abcdef"Jakafi- ruxolitinib tablet". DailyMed. 26 February 2020. Archived from the original on 3 November 2020. Retrieved 16 November 2020.
^"Opzelura- ruxolitinib cream". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
^ abCite error: The named reference Jakavi EPAR was invoked but never defined (see the help page).
^"Opzelura EPAR". European Medicines Agency. 20 April 2023. Archived from the original on 24 April 2023. Retrieved 23 April 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ abcde"Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 12 December 2018. Retrieved 16 February 2014.
^Mesa RA, Yasothan U, Kirkpatrick P (February 2012). "Ruxolitinib". Nature Reviews. Drug Discovery. 11 (2): 103–4. doi:10.1038/nrd3652. PMID 22293561. S2CID 233195859.
^Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S (October 2013). "Practical management of patients with myelofibrosis receiving ruxolitinib". Expert Review of Hematology. 6 (5): 511–23. doi:10.1586/17474086.2013.827413. PMC 8201600. PMID 24083419. S2CID 5470231.
^Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. (January 2015). "Ruxolitinib versus standard therapy for the treatment of polycythemia vera". The New England Journal of Medicine. 372 (5): 426–35. doi:10.1056/NEJMoa1409002. PMC 4358820. PMID 25629741.
^"FDA Approves Jakafi® (Ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera". 4 December 2014. Archived from the original on 8 March 2023. Retrieved 8 March 2023.
^Cite error: The named reference Drug Approval Package: Jakafi was invoked but never defined (see the help page).
^"FDA approves topical treatment". U.S. Food and Drug Administration (FDA) (Press release). 19 July 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022. This article incorporates text from this source, which is in the public domain.
Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type...
Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. Ruxolitinib serves as an inhibitor of JAK...
Food and Drug Administration (FDA) approved the first JAK inhibitor, ruxolitinib, to treat a skin condition. Some JAK1 inhibitors are based on a benzimidazole...
pimecrolimus) are considered to be first-line vitiligo treatments. In July 2022, ruxolitinib cream (sold under the brand name Opzelura) was approved for medical use...
disease. Many clinical trials are ongoing involving JAK inhibitors such as ruxolitinib and tofacitinib. Alopecia areata Alopecia totalis "Alopecia universalis...
by Eli Lilly and Pfizer. Deuruxolitinib is a deuterated derivative of ruxolitinib. King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne;...
published in tandem with a phase II clinical trial showing the same for ruxolitinib. In a June 2015 case report, a 53-year-old woman with vitiligo showed...
arthritis, psoriatic arthritis, and ulcerative colitis; fedratinib, and ruxolitinib. The substance is quickly absorbed from the gut with an absolute bioavailability...
are used in the treatment of seborrheic dermatitis. In September 2021, ruxolitinib cream (Opzelura) was approved by the U.S. Food and Drug Administration...
patients to near-normal life expectancy. Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. Trials of these...
ClinicalTrials.gov Clinical trial number NCT01969838 for "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)" at ClinicalTrials.gov Portal:...
agent) or anagrelide (Agrylin). In Janus kinase 2 positive disorders, ruxolitinib (Jakafi) can be effective.[citation needed] Kumar PJ, Clark ML (2005)...
medications are being studied. In 2014, preliminary findings showing that oral ruxolitinib, a drug approved by the US Food and Drug Administration (FDA) for bone...
cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). Ruxolitinib Fostamatinib Entospletinib Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors...
also effective and safe as a topical treatment for mild-to-moderate AD. Ruxolitinib, a Janus kinase inhibitor, has uncertain efficacy and safety. Oral medications...
disease. However, the first generation of these drugs, tofacitinib and ruxolitinib, lacked subtype selectivity, affecting JAK1/JAK3 and JAK1/JAK2 respectively...
therapies have targeted JAK2 as well as BCR-ABL using nilotinib and ruxolitinib within murine models to downregulate downstream cytokine signaling by...
The molecular formula C17H18N6 may refer to: Deuruxolitinib Ruxolitinib This set index page lists chemical structure articles associated with the same...
of Exjade (which comes in tablets for oral suspension) Jakavi/Jakafi (ruxolitinib) Myelofibrosis (of intermediate to high risk) Kisqali (ribociclib) Breast...
Global Information
(what is this?) (verify)
This article incorporates text from this source, which is in the public domain.
